Cannara Biotech Inc.
LOVE.VTSXVHealthcare
$1.89
+$0.11(+6.18%)
Market Cap$181028256
P/E Ratio—
52W High$2.07
52W Low$1.06
Cannara Biotech Inc. (LOVE.V) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LOVE.V · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Jan 26, 2026EPS Actual
$0.01
Est. $0.01 · +0.0%
Revenue
$0.03B
Est. $0.03B · -0.1%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Jan 26, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
LOVE.V reports quarterly as a TSXV-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 27, 2026 | $0.05 | — | — | — | $0.03B | — |
| — Q1 FY2026 | Jan 26, 2026 | $0.01 | $0.01 | +0.0% | $0.03B | $0.03B | -0.1% |
| — Q4 FY2025 | Nov 24, 2025 | — | $0.04 | — | $0.03B | — | — |
| — Q3 FY2025 | Jul 24, 2025 | — | $0.04 | — | $0.03B | — | — |
| — Q2 FY2025 | Apr 28, 2025 | — | $0.04 | — | $0.03B | — | — |
| — Q1 FY2025 | Jan 27, 2025 | — | $0.03 | — | $0.03B | — | — |
| — Q4 FY2024 | Nov 25, 2024 | — | $0.02 | — | $0.08B | — | — |
| — Q3 FY2024 | Jul 23, 2024 | — | $0.02 | — | $0.02B | — | — |
Q2 FY2026
Apr 27, 2026
EPS Actual
—
EPS Est.
$0.05
EPS Surpr.
—
Revenue
—
Q1 FY2026
Jan 26, 2026
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+0.0%
Revenue
$0.03B
Q4 FY2025
Nov 24, 2025
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q3 FY2025
Jul 24, 2025
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q2 FY2025
Apr 28, 2025
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q1 FY2025
Jan 27, 2025
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q4 FY2024
Nov 25, 2024
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Q3 FY2024
Jul 23, 2024
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.04 | $0.04 | $0.04 | 1 |
| Q2 FY2026 | $0.05 | $0.05 | $0.05 | 1 |
| Q1 FY2026 | $0.05 | $0.05 | $0.05 | 1 |
| Q4 FY2025 | $0.01 | $0.01 | $0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Jan 26, 2026 | +0.0% | $1.92 | $1.93 | +0.52% |
| — Q4 FY2025 | Nov 24, 2025 | — | $1.72 | $1.85 | +7.56% |
| — Q3 FY2025 | Jul 24, 2025 | — | $1.78 | $1.80 | +1.12% |
| — Q2 FY2025 | Apr 28, 2025 | — | $1.40 | $1.42 | +1.43% |
| — Q1 FY2025 | Jan 27, 2025 | — | $0.85 | $0.96 | +12.94% |
| — Q4 FY2024 | Nov 25, 2024 | — | $0.68 | $0.78 | +14.71% |
| — Q3 FY2024 | Jul 23, 2024 | — | $0.58 | $0.60 | +3.45% |
| — Q2 FY2024 | Apr 29, 2024 | — | $0.84 | $0.79 | -5.95% |
Q1 FY2026+0.52%
Report Date
Jan 26, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.92
Price After
$1.93
Q4 FY2025+7.56%
Report Date
Nov 24, 2025
EPS Beat/Miss
—
Price Before
$1.72
Price After
$1.85
Q3 FY2025+1.12%
Report Date
Jul 24, 2025
EPS Beat/Miss
—
Price Before
$1.78
Price After
$1.80
Q2 FY2025+1.43%
Report Date
Apr 28, 2025
EPS Beat/Miss
—
Price Before
$1.40
Price After
$1.42
Q1 FY2025+12.94%
Report Date
Jan 27, 2025
EPS Beat/Miss
—
Price Before
$0.85
Price After
$0.96
Q4 FY2024+14.71%
Report Date
Nov 25, 2024
EPS Beat/Miss
—
Price Before
$0.68
Price After
$0.78
Q3 FY2024+3.45%
Report Date
Jul 23, 2024
EPS Beat/Miss
—
Price Before
$0.58
Price After
$0.60
Q2 FY2024-5.95%
Report Date
Apr 29, 2024
EPS Beat/Miss
—
Price Before
$0.84
Price After
$0.79
Avg Beat Reaction+0.52%
Beat Rate1 / 8 quarters
Largest Move+14.71% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LOVE.V ends December
Cannara Biotech Inc. (LOVE.V) most recently reported earnings on January 26, 2026 for Q1 FY2026, posting EPS of $0.01 (in line with the analyst consensus of $0.01). The next LOVE.V earnings date is expected around September 1, 2026.
Each quarter, investors track LOVE.V earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LOVE.V revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LOVE.V's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LOVE.V earnings · 4 questionsCannara Biotech Inc.'s next earnings report is expected around September 1, 2026. LOVE.V typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LOVE.V historically reports after market close (AMC).
LOVE.V earnings datewhen is LOVE.V earningsLOVE.V next earnings datewhen does LOVE.V report earningsLOVE.V earnings calendar
▸ Source: FMP · Cannara Biotech Inc. SEC filings · US GAAP · Cannara Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026